Author: David Cooper

Downloads per author, site-wide

Preprints

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

• Downloaded 65,971 times
• Download rankings, all-time:
  • Site-wide: 75
  • In infectious diseases: 30
• Year to date:
  • Site-wide: 180
• Since beginning of last month:
  • Site-wide: 285

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

• Downloaded 61,310 times
• Download rankings, all-time:
  • Site-wide: 83
  • In infectious diseases: 33
• Year to date:
  • Site-wide: 57
• Since beginning of last month:
  • Site-wide: 71

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 51,654 times
• Download rankings, all-time:
  • Site-wide: 100
  • In microbiology: 8
• Year to date:
  • Site-wide: 2
• Since beginning of last month:
  • Site-wide: 42

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

• Downloaded 21,731 times
• Download rankings, all-time:
  • Site-wide: 301
  • In infectious diseases: 112
• Year to date:
  • Site-wide: 413
• Since beginning of last month:
  • Site-wide: 563

Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 20,704 times
• Download rankings, all-time:
  • Site-wide: 316
  • In microbiology: 33
• Year to date:
  • Site-wide: 24
• Since beginning of last month:
  • Site-wide: 11

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

• Downloaded 10,061 times
• Download rankings, all-time:
  • Site-wide: 754
  • In infectious diseases: 228
• Year to date:
  • Site-wide: 80
• Since beginning of last month:
  • Site-wide: 108